Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease
| Autor: | Bo-Lin Yang, Wan-Jin Shao, Gui-Dong Sun, Ping Zhu, Yu-Gen Chen, Hong-Jin Chen, Yunfei Gu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Anal fistula
musculoskeletal diseases Adult Male medicine.medical_specialty China Time Factors Adolescent Fistula Tertiary Care Centers Young Adult Maintenance therapy Crohn Disease medicine Combined Modality Therapy Humans Rectal Fistula Prospective Studies Prospective cohort study skin and connective tissue diseases Crohn's disease Wound Healing medicine.diagnostic_test business.industry Gastroenterology Antibodies Monoclonal General Medicine medicine.disease Magnetic Resonance Imaging Infliximab digestive system diseases Surgery stomatognathic diseases Treatment Outcome Erythrocyte sedimentation rate Prospective Study Female business Immunosuppressive Agents medicine.drug |
| Popis: | AIM: To evaluate the efficacy and long-term outcome of infliximab combined with surgery to treat perianal fistulizing Crohn’s disease (CD). METHODS: The work was performed as a prospective study. All patients received infliximab combined with surgery to treat perianal fistulizing CD, which was followed by an immunosuppressive agent as maintenance therapy. RESULTS: A total of 28 patients with perianal fistulizing CD were included. At week 30, 89.3% (25/28) of the patients were clinically cured with an average healing time of 31.4 d. The CD activity index decreased to 70.07 ± 77.54 from 205.47 ± 111.13 (P < 0.01) after infliximab treatment. The perianal CD activity index was decreased to 0.93 ± 2.08 from 8.54 ± 4.89 (P < 0.01). C-reactive protein, erythrocyte sedimentation rate, platelets, and neutrophils all decreased significantly compared with the pretreatment levels (P < 0.01). Magnetic resonance imaging results for 16 patients after therapy showed that one patient had a persistent presacral-rectal fistula and another still had a cavity without clinical symptoms at follow-up. After a median follow-up of 26.4 mo (range: 14-41 mo), 96.4% (27/28) of the patients had a clinical cure. CONCLUSION: Infliximab combined with surgery is effective and safe in the treatment of perianal fistulizing CD, and this treatment was associated with better long-term outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|